Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systembenzodiazepines, alcohol, barbiturates +1 morebenzodiazepines, alcohol, barbiturates, other GABAergic CNS depressants show less
Flubromazepam
Flubromazepam is a synthetic depressant of the benzodiazepine class. It belongs to the same drug family as diazepam (Valium) but lasts far longer — effects persist for days after a single dose. It amplifies the brain's primary inhibitory signaling system, producing sedation, anxiety relief, and muscle relaxation.
Flubromazepam is a synthetic depressant of the benzodiazepine class. It is structurally related to phenazepam, distinguished by an ultra-long half-life exceeding 100 hours.[1] Flubromazepam is a presumed positive allosteric modulator of GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory neurotransmitter system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systembenzodiazepines, alcohol, barbiturates +1 morebenzodiazepines, alcohol, barbiturates, other GABAergic CNS depressants show less
Flubromazepam was synthesized around 1960 during the first wave of benzodiazepine chemistry, but was never clinically developed or marketed.[1] It resurfaced in late 2012 on internet research chemical markets, one of the first three designer benzodiazepines sold online.[1][2] It is now controlled in the United States and United Kingdom, and has appeared as an undisclosed contaminant in the illicit opioid supply.[3]
Subjective effects include anxiety suppression, heavy sedation, muscle relaxation, amnesia, and disinhibition. The experience is unremarkable in character — a gradual dampening of tension that deepens into sedation — but is defined by extraordinary persistence, with impairment lasting days after a single dose. Memory blackouts and a convincing false sense of sobriety are characteristic, driving users to redose without any memory of prior doses.
Flubromazepam produces physical dependence, and abrupt cessation can cause life-threatening seizures; all documented deaths involve combinations with opioids or other depressants.[4][5][6] The extreme half-life causes silent accumulation — users may not realize they are still intoxicated and redose, which is the primary acute danger. Human knowledge is very limited: one self-experiment, forensic case reports, and inference from established benzodiazepine pharmacology.[1]
History[edit]
Discovery
Flubromazepam was synthesized around 1960 during the rapid expansion of benzodiazepine chemistry that followed the first successful benzodiazepines.citation needed Like hundreds of analogs produced in that era, it never reached clinical trials or the market, and remained an obscure research compound for over fifty years.[1]
Emergence as a designer drug
The compound resurfaced in late 2012 on internet research chemical markets, appearing alongside diclazepam and pyrazolam as one of the first three designer benzodiazepines sold online.[1][2] The only published human pharmacokinetic study followed in 2013, based on a single researcher self-experiment at 4 mg oral.[1]
Prohibition and modern circulation
The United Kingdom classified flubromazepam as Class C in 2017,[7] and the US Drug Enforcement Administration placed it temporarily in Schedule I in 2023.[8] Despite controls, it has appeared in the illicit opioid supply in Vancouver[3] and in Scottish prisons, where seized tablets showed nearly sevenfold variation in drug content per tablet.[9]
The name flubromazepam follows standard benzodiazepine nomenclature: flu- for fluorine, -bro- for bromine, and -mazepam denoting the 1,4-benzodiazepine scaffold. It should not be confused with flubromazolam, its far more potent triazolo-fused analog — a confusion with potentially fatal consequences.[2] Among users, flubromazepam's primary reputation is for extreme duration, with multi-day residual impairment discussed as both a warning and a distinguishing feature.
Chemistry[edit]
Structural class
Flubromazepam belongs to the 1,4-benzodiazepine family — the same chemical scaffold as diazepam and phenazepam. It differs from phenazepam by a single substitution: fluorine in place of chlorine at one position of the 5-phenyl ring.citation needed Its triazolo structural analog flubromazolam is a distinct, far more potent compound that should not be confused with flubromazepam.[2]
Molecular properties
| Molecular formula | C₁₅H₁₀BrFN₂O |
| Molecular weight | 333.15 g/mol |
The molecule has a seven-membered diazepine ring fused to a brominated benzene ring, with a fluorine-bearing phenyl group and a carbonyl group — classifying it as a 2-keto benzodiazepine. These structural features were confirmed by NMR and mass spectrometry.[1] Flubromazepam lacks a chirality center and exists as a single achiral species.
Pharmacology[edit]
Mechanism of action
Flubromazepam amplifies the activity of GABA-A receptors — the brain's primary inhibitory signaling system — increasing the frequency of channel opening when GABA is present.[10] This produces the characteristic benzodiazepine profile: anxiety relief, sedation, muscle relaxation, and memory suppression. No potency or binding data have been published; all mechanistic conclusions are inferred from structural class membership.[10]inferred
Pharmacokinetics
The only human data come from a single self-experiment at 4 mg oral.[1] The half-life exceeds 100 hours — among the longest of any known benzodiazepine — and the compound remained detectable for up to 31 days after that single dose.
The primary urinary metabolite, 3-hydroxyflubromazepam, is detectable for up to 28 days and is the recommended target for drug testing.[1] The liver enzymes responsible for metabolism are unknown; the class-typical CYP3A4 pathway is plausible.[11]inferred
Neuroscience[edit]
Where it acts
Flubromazepam enhances inhibitory signaling across many brain regions simultaneously — sedating the cortex and thalamus, suppressing fear responses in the amygdala, disrupting memory formation in the hippocampus, and at high doses or in combination with other depressants, suppressing breathing by dampening brainstem respiratory centers.inferred
Why it matters
The extreme half-life means sustained receptor occupancy for days after a single dose — unlike shorter-acting benzodiazepines where effects cycle on and off.inferred Residual impairment persists well beyond any feeling of being intoxicated, and repeated dosing compounds receptor exposure.
Chronic exposure drives the brain to reduce the sensitivity of its inhibitory receptors — the molecular basis of tolerance and withdrawal.inferred Whether flubromazepam's prolonged occupancy accelerates or delays this process compared to shorter-acting compounds is unknown.
- Does flubromazepam's sustained receptor occupancy produce a distinctive withdrawal profile compared to shorter-acting benzodiazepines?
- Does the 2-fluorophenyl substitution confer any preference for specific GABA-A subtypes relative to phenazepam?
- How does residual receptor activity at 24–72 hours post-dose contribute to functional impairment in daily activities?
Subjective Effects[edit]
Flubromazepam delivers the classical benzodiazepine experience — a progressive quieting of anxiety and physical tension that deepens into heavy sedation. What defines it is not the character of intoxication, which is unremarkable compared to pharmaceutical benzodiazepines, but its extraordinary persistence: impairment continues well beyond any subjective sense of being intoxicated.
Within the designer benzodiazepine landscape, flubromazepam occupies a low-potency, ultra-long-duration niche — closer in character and accumulation risk to phenazepam than to its triazolo structural analog flubromazolam, which is far more potent but shorter-acting.[2] Users frequently underestimate its residual effects.[1]
Synthesized around 1960 during the first wave of benzodiazepine pharmaceutical development, flubromazepam was never clinically developed or marketed.[1] It resurfaced in late 2012 as one of the first three designer benzodiazepines sold on internet research chemical markets, alongside diclazepam and pyrazolam.[3] It is now controlled in several jurisdictions including the United States and United Kingdom, though it remains outside international scheduling.
Subjective effects include anxiolysis, sedation, muscle relaxation, amnesia, and disinhibition. The experience is a slow, heavy dampening of anxiety and physical tension that settles into deep sedation — unremarkable in character but defined by extraordinary persistence, with residual cognitive blunting lasting days after a single dose. Anterograde amnesia, delusions of sobriety, and compulsive redosing without recall of prior doses are characteristic unsought effects.
Flubromazepam produces physical dependence with continuous use, and abrupt cessation has caused life-threatening withdrawal seizures.[4] All documented fatalities involve opioid or polydrug combinations[5][6] — the compound's extreme half-life makes accumulation during repeated dosing the primary acute danger, as users may not recognize ongoing intoxication. No controlled studies have been conducted in humans; the current understanding rests on a single self-experiment, forensic case reports, and inference from established benzodiazepine pharmacology.[1]
History[edit]
Discovery
Flubromazepam was synthesized around 1960 during the rapid expansion of benzodiazepine chemistry following Leo Sternbach's discovery of chlordiazepoxide.citation needed Like hundreds of analogs produced in this era, it was never advanced to clinical trials, never patented, and never marketed — remaining what one characterization termed a "poorly characterized research drug candidate" for over five decades.[1]
Emergence as a designer drug
The compound resurfaced in late 2012 on internet research chemical markets alongside diclazepam and pyrazolam — the first three designer benzodiazepines available for online purchase.[1][3] Their appearance marked a structural shift in the novel psychoactive substance landscape: for the first time, the benzodiazepine scaffold entered the grey-market supply chain at scale. The sole published human pharmacokinetic study followed in 2013, based on a single researcher self-experiment at 4 mg oral.[1]
Prohibition and modern circulation
The United Kingdom classified flubromazepam as Class C in 2017,[7] and the US Drug Enforcement Administration placed it in Schedule I temporarily in 2023.[8] Despite controls, flubromazepam has appeared in the unregulated opioid supply in Vancouver[9] and in Scottish prisons, where demand migrated from scheduled etizolam and seized tablets showed wide dosing variability (0.34–2.33 mg per tablet).[10]
The name flubromazepam follows standard benzodiazepine nomenclature: flu- for the fluorine substituent, -bro- for bromine, and -mazepam denoting the 1,4-benzodiazepine scaffold with a 2-keto group. It should not be confused with flubromazolam, its triazolo-fused analog, which is far more potent — a confusion with potentially fatal consequences given the compounds' similar names.[3] Among users, flubromazepam's primary reputation is for its extreme duration, with forum discussions frequently emphasizing multi-day residual impairment as both a warning and a distinguishing feature.
Chemistry[edit]
Structural class
Flubromazepam belongs to the 1,4-benzodiazepine family, sharing the fused benzene-diazepine ring system first developed by Leo Sternbach in the late 1950s. It is structurally related to phenazepam, differing by a fluorine-for-chlorine substitution at the 2-position of the 5-phenyl ring.citation needed Its triazolo structural analog flubromazolam — which incorporates a fused triazole ring — is a distinct and substantially more potent compound that should not be confused with flubromazepam.[3]
Molecular properties
| Molecular formula | C₁₅H₁₀BrFN₂O |
| Molecular weight | 333.15 g/mol |
The molecule features a seven-membered diazepine ring fused to a brominated benzene ring at the 7-position, a 2-fluorophenyl group at the 5-position, and a carbonyl at the 2-position — classifying it as a 2-keto benzodiazepine. These structural elements were confirmed by NMR and mass spectrometry in the first published characterization.[1]
Stereochemistry
Flubromazepam lacks a chirality center and exists as a single achiral species. The diazepine ring can adopt transient boat-like conformations, but this is not pharmacologically relevant for receptor binding.
Physical properties
No published data on melting point, solubility, or stability exist. The compound has been encountered as a white to off-white powder and in tablet form.[10] Tablets seized from Scottish prison populations varied widely in drug content (0.34–2.33 mg per tablet), reflecting inconsistent clandestine manufacture.[10]
Pharmacology[edit]
Mechanism of action
Flubromazepam enhances the activity of GABA-A receptors — the brain's primary inhibitory signaling system. It binds at the interface between receptor subunits and increases the frequency of chloride ion channel opening when GABA is present, amplifying the brain's natural braking signals.[2] This mechanism is shared across the benzodiazepine class and produces the characteristic profile of anxiety reduction, sedation, muscle relaxation, and memory suppression.
No binding affinity or potency measurements have been published for flubromazepam at any receptor subtype. Whether it preferentially affects the subtypes responsible for sedation versus anxiolysis versus memory impairment is entirely unknown.[2] All mechanistic conclusions are inferred from its structural membership in the benzodiazepine class.inferred
Pharmacokinetics
The only human pharmacokinetic data come from a single researcher self-experiment at 4 mg oral.[1] No controlled clinical studies have been conducted.
The half-life exceeds 100 hours, placing flubromazepam among the longest-acting benzodiazepines known — comparable to or exceeding diazepam's active metabolite desmethyldiazepam.[1] The compound remained detectable for up to 31 days after a single dose. Peak concentration timing and oral bioavailability have not been measured.
The primary urinary metabolite is 3-hydroxyflubromazepam, detectable for up to 28 days after ingestion and recommended as the target analyte for drug testing.[1] A minor debrominated metabolite and glucuronide conjugates have also been identified. The specific liver enzymes responsible for metabolism are unknown, though the class-typical CYP3A4 pathway is plausible.[11]inferred
Neuroscience[edit]
Where it acts
Flubromazepam amplifies inhibitory signaling across widespread brain regions. Enhanced GABA-A activity in the cortex and thalamus produces sedation and cognitive slowing; in the amygdala, it dampens fear responses to produce anxiolysis; in the hippocampus, it disrupts memory formation, accounting for the prominent anterograde amnesia; and in spinal cord and brainstem motor circuits, it relaxes skeletal muscle.inferred At high doses or in combination with other depressants, inhibition of brainstem respiratory centers can suppress breathing — the mechanism underlying benzodiazepine-related fatality.
Why it matters
The extreme half-life (>100 hours) means flubromazepam maintains receptor occupancy for days after a single dose, unlike shorter-acting benzodiazepines where occupancy cycles rapidly. This sustained occupancy has two consequences: residual functional impairment persists well beyond perceived intoxication, and repeated dosing produces cumulative receptor exposure that may accelerate the development of physical dependence.
Chronic exposure drives GABA-A receptor downregulation and uncoupling — the molecular basis of tolerance and withdrawal. Whether flubromazepam's prolonged occupancy accelerates or delays this adaptation relative to shorter-acting compounds is unknown.inferred
- Does flubromazepam's sustained receptor occupancy produce a distinctive withdrawal profile compared to shorter-acting benzodiazepines?
- Does the 2-fluorophenyl substitution confer any preference for specific GABA-A receptor subtypes relative to the 2-chlorophenyl group of phenazepam?
- How does residual receptor occupancy at 24–72 hours post-dose contribute to functional impairment in daily activities?
Subjective Effects[edit]
Flubromazepam delivers the classical benzodiazepine experience — a progressive dissolution of anxiety and muscle tension that deepens into heavy sedation at higher doses. What defines it is not the character of intoxication, which is unremarkable relative to pharmaceutical benzodiazepines, but its extraordinary persistence: residual cognitive blunting, motor impairment, and emotional flattening continue well beyond the window of perceived intoxication, and repeated dosing produces insidious accumulation that users frequently underestimate.[1]
Within the designer benzodiazepine landscape, flubromazepam occupies a low-potency, ultra-long-acting niche — closer in duration and accumulation risk to phenazepam than to its own triazolo structural analog flubromazolam, which is far more potent but substantially shorter-acting.[3]
Effect Grid
Pronounced sedation dominates the common dose range, accompanied by clear anxiety suppression and substantial muscle relaxation. Anterograde amnesia becomes likely — users may not retain memories formed during the experience. Analysis suppression and thought deceleration are prominent, and disinhibition alters judgment and risk assessment.
Motor control impairment is noticeable; coordination is reduced sufficiently to make driving hazardous. Dizziness may occur. Appetite enhancement is more likely at this level. Emotional suppression flattens the affective range.
Residual cognitive blunting and motor impairment extend well beyond the perceived 6-12 hour effect window. Any repeated dosing at this level produces rapid accumulation — a daily common dose becomes a strong or heavy effective dose within days due to the >100-hour half-life.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Bodily heaviness · Dizziness · Body high · Nystagmus (eye wobbles) · Yawning · Tactile euphoria · Sexual arousal suppression · Dry mouth · Headache · Appetite enhancement · Sexual arousal enhancement · Nausea · Laughter fits · Restlessness · Stimulation · Vomiting · Bodily dissociation
Yawning · Tactile euphoria · Sexual arousal suppression · Dry mouth · Headache · Appetite enhancement · Sexual arousal enhancement · Nausea · Laughter fits · Restlessness · Stimulation · Vomiting · Bodily dissociation
Analysis suppression · Focus suppression · Information processing suppression · Motivation suppression · Cognitive fatigue · Memory fragmentation · Suggestibility enhancement · Cognitive euphoria · Thought disorganization · Language suppression · Compulsive redosing urge · Confusion · Amnesia
Motivation suppression · Cognitive fatigue · Memory fragmentation · Cognitive euphoria · Thought disorganization · Language suppression · Compulsive redosing urge · Confusion · Amnesia
Anhedonia · Emotional lability · Anxiety · Dysphoria
Trust enhancement · Automaticity · Craving · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Depersonalization · Derealization · Cognitive disconnection
Timeline
Gradual emergence of anxiolysis and mild relaxation. A subtle easing of tension becomes perceptible, though effects may initially be difficult to distinguish from placebo.
Progressive deepening of sedation and muscle relaxation. Thought deceleration becomes noticeable and mild cognitive blunting sets in.
Maximum sedation, anxiolysis, amnesia, and muscle relaxation. Disinhibition and delusions of sobriety may drive compulsive redosing at higher doses. Motor coordination is significantly impaired.
Gradual reduction in perceived effects, though pharmacological activity continues. Sedation and cognitive blunting diminish but motor impairment may persist unnoticed.
Residual sedation, cognitive blunting, and subtle motor impairment persist due to the >100-hour elimination half-life. Functional impairment may be present without subjective awareness.
⚠ Do not drive or operate heavy machinery for at least 48 hours after dosing; residual impairment may persist for several days.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
No lethal dose has been established for flubromazepam in any species. No controlled toxicity studies have been conducted.
Acute toxicity
All documented deaths involve polydrug combinations, particularly with opioids.[6][5] In one case, a 28-year-old was found deceased with flubromazepam alongside U-47700, diclazepam, and methamphetamine; death was attributed to aspiration from mixed drug toxicity.[6] Post-mortem identifications have been documented in Norway.[12]
In a systematic review of designer benzodiazepine adverse events, most fatalities were linked to other compounds — etizolam, flualprazolam, flubromazolam, and phenazepam — rather than flubromazepam.[13]
Drug supply contamination
Flubromazepam has been detected in the illicit opioid supply in Vancouver from mid-2018 onward.[3] People using opioids may unknowingly consume flubromazepam alongside them, adding respiratory depression from a benzodiazepine they didn't know they had taken.
Overdose recognition and management
Benzodiazepine overdose presents as progressive sedation, loss of coordination, slurred speech, and at severe levels, coma and respiratory failure.
Flumazenil — a competitive benzodiazepine antagonist — reverses sedation and has been confirmed effective in structural analog overdose.[14] Its effects last only about 60 minutes, far shorter than flubromazepam's half-life, so re-sedation is expected — repeat dosing or continuous infusion may be required. Flumazenil is contraindicated in benzodiazepine-dependent patients and in mixed overdoses involving seizure-causing substances.
Psychological Risks
Amnesia is prominent at moderate-to-strong doses. Combined with delusions of sobriety, this creates a dangerous cycle — users may not recall having dosed and take more, escalating exposure without awareness.[14] Disinhibition impairs judgment, contributing to dangerous behaviors including driving under the influence.[15]
Cognitive impairment can persist for days beyond perceived intoxication. Prolonged use produces emotional suppression, motivational suppression, and progressive cognitive deterioration. Drug-facilitated sexual assault using designer benzodiazepines including flubromazepam has been documented, exploiting its amnestic properties.[16]
Tolerance & Dependence
Physical dependence with severe withdrawal is confirmed for flubromazepam. A withdrawal seizure following abrupt cessation has been documented.[4] Benzodiazepine withdrawal can include seizures, anxiety, insomnia, tremor, perceptual disturbances, and autonomic instability — seizures are the life-threatening component.
Tolerance develops rapidly, driven by GABA-A downregulation.[14] The extreme half-life means dependence can develop even with infrequent use. Cross-tolerance with alcohol, barbiturates, and other GABAergic depressants is expected.
Drug Interactions
Opioids (lethal)
Combining flubromazepam with opioids suppresses breathing through two complementary pathways — both act on brainstem respiratory centers, and the combined effect is additive and potentially fatal.[5][6] Flubromazepam's presence in the illicit opioid supply creates the risk of unintentional co-exposure.[3]
Other CNS depressants
Alcohol, barbiturates, gabapentinoids (pregabalin, gabapentin), GHB, and other benzodiazepines all add to respiratory depression when combined with flubromazepam. Polydrug deaths document co-detection with diazepam[5] and diclazepam.[6]
Kratom
Kratom (Mitragyna speciosa) both inhibits benzodiazepine metabolism and adds opioid-like respiratory depression through its own activity at opioid receptors.[4] This dual interaction complicated management in a documented flubromazepam withdrawal case.
CYP3A4 inhibitors
If flubromazepam is metabolized via the CYP3A4 pathway — plausible given its class — co-administration with inhibitors such as ketoconazole, ritonavir, or grapefruit juice would raise plasma levels and extend an already extreme half-life.inferred
Contraindications
10 knownAbsolute
- Concurrent opioid use: Combined respiratory depression with documented fatalities.[5][6]
- Active benzodiazepine dependence requiring flumazenil reversal: Risk of triggering withdrawal seizures.
Relative
- Concurrent alcohol or other CNS depressant use: Additive respiratory depression.inferred
- Respiratory compromise or obstructive sleep apnea: Benzodiazepine-mediated respiratory depression may cause respiratory failure in those with compromised baseline breathing.inferred
- Pregnancy: Benzodiazepines as a class carry risk of birth defects.inferred
- Liver impairment: Reduced metabolic clearance would prolong an already extreme half-life.inferred
- Elderly patients: Age-related reductions in metabolism increase sensitivity.inferred
- History of substance use disorder: High reinforcement potential and compulsive redosing risk.
Harm Reduction[edit]
Forms & Identification
Flubromazepam's presence in the illicit opioid supply[3] means exposure can occur without awareness. Standard urine drug screens do not reliably detect designer benzodiazepines — specialized laboratory testing targeting 3-hydroxyflubromazepam is required for confirmation.[1]
Tablets from unregulated sources show nearly sevenfold variation in drug content per tablet.[9] No two tablets from the same source can be assumed to contain equal doses.
Guidelines
- Test all substances before use. Reagent testing cannot confirm flubromazepam specifically but can exclude some common substitutions.
- Start with the lowest available dose. The long onset and extreme half-life mean effects accumulate — do not redose within 24 hours.
- Write down the time and amount of each dose. Amnesia makes mental tracking unreliable — a written log is the only reliable safeguard against compulsive redosing.
- Avoid all other depressants, including alcohol, for the duration of effects and at least 72 hours afterward.
- Have a sober companion present who understands the compound's amnestic properties and can prevent redosing.
- Do not drive or operate machinery for a minimum of 3 days after dosing.
Set & Setting
The extreme duration demands planning that most benzodiazepine users don't anticipate. Residual impairment persists for days — not hours — after a single dose.
Operating vehicles or machinery should be avoided for at least 72 hours. A trusted sober companion is advisable, particularly given the compound's ability to produce amnesia and a convincing but false sense of sobriety at moderate doses.
Aftercare & integration. Cognitive impairment, slowed reactions, and emotional flatness may persist for 3–5 days after a single dose and longer after repeated use. During this period, prioritize sleep, hydration, and light nutrition. Avoid demanding cognitive tasks and do not drive.
Memory gaps from the experience are common. If companions were present, ask them to describe events that may not be recalled. Persistent amnesia, emotional numbness, or difficulty concentrating beyond one week warrants medical evaluation.
Recovery & Support
Benzodiazepine dependence requires supervised treatment. Abrupt cessation of flubromazepam can produce life-threatening seizures — never stop use suddenly without medical guidance.[4] No established diazepam equivalency exists, so withdrawal management requires symptom-guided titration under clinical supervision.
Resources include the Benzodiazepine Information Coalition (benzoinfo.com), the SAMHSA National Helpline (1-800-662-4357), and medical providers experienced in GABAergic withdrawal management. Online communities such as BenzoBuddies provide peer support, though medical supervision remains essential for any taper.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unrousable sedation, slow or shallow breathing, blue-tinged lips or fingertips, loss of consciousness, or seizures. Difficulty waking someone who has taken flubromazepam is a medical emergency — do not wait to see if they improve.
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position (on their side with the top knee drawn forward) to prevent choking.
- 3. Monitor breathing continuously. If breathing stops, begin rescue breathing if trained.
- 4. Do not induce vomiting.
- 5. Do not leave the person alone.
What to tell the dispatcher: Name the substance (flubromazepam, a designer benzodiazepine), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Reversal agent: Flumazenil reverses benzodiazepine sedation but wears off in approximately 60 minutes — far shorter than flubromazepam's effects. Re-sedation is likely, and medical monitoring after administration is essential. Flumazenil can trigger seizures in benzodiazepine-dependent individuals.
Legal Status[edit]
Flubromazepam is controlled in several major jurisdictions but is not subject to international scheduling — the WHO reviewed it in 2023 and did not recommend international control.[17]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (temporary) | DEA temporary emergency placement effective July 26, 2023; permanent status requires verification[8]safety citation needed |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Specifically scheduled May 2017; also covered by Psychoactive Substances Act 2016[7][18] |
| Canada | Schedule IV (CDSA) | Controlled Drugs and Substances Act[17] |
| Germany | Controlled (NpSG) | Neue-psychoaktive-Stoffe-Gesetz[17] |
| United Arab Emirates | Controlled | National psychoactive substance regulations[17] |
| International | Not under international control | WHO ECDD 46th review (2023) did not recommend scheduling[17] |
Analog act considerations
In jurisdictions without specific scheduling, flubromazepam may fall under structural analog legislation. In the United States, the Federal Analogue Act treats substances structurally similar to Schedule I/II drugs as controlled when intended for human consumption — flubromazepam's structural similarity to scheduled benzodiazepines makes analog prosecution plausible.[19][20]
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
No LD₅₀ has been established for flubromazepam in any species. No controlled toxicity studies have been conducted, and no therapeutic index can be calculated.
Acute toxicity
No published case of death attributed solely to flubromazepam exists. All documented fatalities involve polydrug combinations, particularly opioids: a 28-year-old male was found deceased with flubromazepam (10 µg/L), U-47700, diclazepam, and methylamphetamine, with death attributed to aspiration from mixed drug toxicity.[6] A separate fatality involved flubromazepam (480 ng/mL) alongside U-47700, methadone, and diazepam.[5]
Retrospective post-mortem identifications have been documented in Norway.[12] In a systematic review of designer benzodiazepine adverse events, the majority of fatalities were linked to etizolam, flualprazolam, flubromazolam, and phenazepam rather than flubromazepam.[13]
Drug supply contamination
Flubromazepam has been detected in the unregulated opioid supply in Vancouver, Canada from mid-2018 onward.[9] Opioid-dependent individuals may unknowingly consume flubromazepam alongside opioids, producing combined respiratory depression without awareness of benzodiazepine co-exposure.
Overdose recognition and management
Benzodiazepine overdose presents as progressive sedation, loss of coordination, slurred speech, and — at severe levels — coma and respiratory failure. Pinpoint pupils and muscle breakdown have been documented in overdose with the structural analog flubromazolam.[14]
Flumazenil (a competitive benzodiazepine antagonist) reverses sedation and has been confirmed effective in structural analog overdose.[14] Its short duration of action (approximately 60 minutes) relative to flubromazepam's half-life (>100 hours) means re-sedation is expected — repeat dosing or continuous infusion may be required. Flumazenil is contraindicated in benzodiazepine-dependent patients (risk of triggering withdrawal seizures) and in mixed overdoses with seizure-causing substances.
Psychological Risks
Amnesia is a prominent risk at moderate-to-strong doses. Combined with delusions of sobriety, this creates a dangerous cycle: users may not recall having already dosed and redose repeatedly, escalating exposure without awareness of ongoing intoxication.[14]
Disinhibition impairs judgment and risk assessment, contributing to dangerous behaviors including driving under the influence.[15]
Cognitive impairment persists beyond perceived intoxication due to the compound's extreme half-life — users may experience subtle but functionally significant impairment for days. Prolonged use produces emotional suppression, motivational suppression, and progressive cognitive deterioration.
Drug-facilitated sexual assault using designer benzodiazepines including flubromazepam has been documented, exploiting the compound's amnestic properties and evasion of standard drug screening.[16]
Tolerance & Dependence
Physical dependence with severe withdrawal is confirmed for flubromazepam. A case of withdrawal seizure following abrupt cessation has been documented (in combination with bromazolam, alcohol, kratom, tianeptine, and phenibut).[4] Benzodiazepine withdrawal can include seizures, anxiety, insomnia, tremor, perceptual disturbances, and autonomic instability — seizures are the life-threatening component.
Tolerance develops rapidly, driven by GABA-A downregulation.[14] Flubromazepam's extreme half-life produces sustained receptor occupancy that facilitates dependence even with infrequent dosing by calendar time. Cross-tolerance with other benzodiazepines, alcohol, barbiturates, and other GABAergic depressants is expected.
No established diazepam equivalency exists for flubromazepam. Symptom-based withdrawal management (CIWA-guided diazepam titration) is the necessary approach when equivalency is unknown.[4] Abrupt cessation without medical supervision can produce life-threatening seizures.
Drug Interactions
Opioids (lethal)
The combination of flubromazepam with opioids is the best-documented lethal interaction. Multiple polydrug deaths involve this combination,[5][6] and flubromazepam's presence in unregulated opioid supply creates inadvertent co-exposure.[9] Both drug classes suppress breathing through complementary brainstem mechanisms, producing combined respiratory depression.
Other CNS depressants
Alcohol, barbiturates, gabapentinoids (pregabalin, gabapentin), GHB, and other benzodiazepines all produce additive respiratory depression when combined with flubromazepam. Polydrug fatalities document co-detection with diazepam[5] and diclazepam.[6]
Kratom
Kratom (Mitragyna speciosa) inhibits benzodiazepine metabolism and adds opioid-like respiratory depression via its own activity at µ-opioid receptors.[4] This dual pharmacokinetic-pharmacodynamic interaction complicated management in a documented flubromazepam withdrawal case.
CYP3A4 inhibitors
If flubromazepam follows the class-typical CYP3A4 metabolic pathway, co-administration with CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice) would increase plasma levels and prolong an already extreme half-life.inferred
Contraindications
10 knownAbsolute
- Concurrent opioid use: Combined respiratory depression with documented fatalities.[5][6]
- Active benzodiazepine dependence requiring flumazenil reversal: Risk of triggering withdrawal seizures.
Relative
- Concurrent alcohol or other CNS depressant use: Additive respiratory depression.inferred
- Respiratory compromise or obstructive sleep apnea: Benzodiazepine-mediated respiratory depression may cause respiratory failure in those with compromised baseline breathing.inferred
- Pregnancy: Benzodiazepines as a class carry risk of birth defects.inferred
- Liver impairment: Reduced metabolic clearance would prolong an already extreme half-life.inferred
- Elderly patients: Age-related reductions in metabolism increase sensitivity.inferred
- History of substance use disorder: High reinforcement potential and compulsive redosing risk.
Harm Reduction[edit]
Forms & Identification
Flubromazepam's presence in the unregulated opioid supply[9] means exposure can occur without the user's knowledge. Standard immunoassay urine drug screens do not reliably detect designer benzodiazepines — specialized LC-MS/MS testing targeting 3-hydroxyflubromazepam is required for confirmation.[1] The nearly sevenfold variation in tablet drug content documented in forensic seizures[10] means no two tablets from an unregulated source can be assumed equivalent.
Guidelines
- Test all substances before use. Reagent testing cannot confirm flubromazepam specifically but can exclude some common substitutions.
- Start with the lowest available dose. The long onset and extreme half-life mean effects accumulate — do not redose within 24 hours.
- Write down the time and amount of each dose. Amnesia makes mental tracking unreliable — a written log is the only reliable safeguard against compulsive redosing.
- Avoid all other depressants, including alcohol, for the duration of effects and at least 72 hours afterward.
- Have a sober companion present who understands the compound's amnestic properties and can prevent redosing.
- Do not drive or operate machinery for a minimum of 3 days after dosing.
Set & Setting
The extreme duration of flubromazepam's effects demands planning that most benzodiazepine users do not anticipate. Residual impairment persists for days — not hours — after a single dose. Operating vehicles, machinery, or making consequential decisions should be avoided for at least 72 hours. A trusted sober companion is advisable, particularly given the compound's capacity to produce amnesia and delusions of sobriety at moderate doses.
Aftercare & integration. The extended duration of flubromazepam's effects makes aftercare unusually important. Cognitive impairment, slowed reactions, and emotional flatness may persist for 3–5 days after a single dose and longer after repeated use. During this period, prioritize sleep, hydration, and light nutrition. Avoid demanding cognitive tasks and do not drive.
Memory gaps from the experience are common. If companions were present, ask them to describe events you may not recall. Persistent amnesia, emotional numbness, or difficulty concentrating beyond one week warrants medical evaluation.
Recovery & Support
Benzodiazepine dependence is a medical condition requiring supervised treatment. Abrupt cessation of flubromazepam can produce life-threatening seizures — never stop use suddenly without medical guidance.[4] No established diazepam equivalency exists for flubromazepam, so withdrawal management requires symptom-guided titration under clinical supervision.
Resources for benzodiazepine dependence include the Benzodiazepine Information Coalition (benzoinfo.com), the SAMHSA National Helpline (1-800-662-4357), and medical providers experienced in GABAergic withdrawal management. Online communities such as BenzoBuddies provide peer support, though medical supervision remains essential for any taper.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unrousable sedation, slow or shallow breathing, blue-tinged lips or fingertips, loss of consciousness, or seizures. Difficulty waking someone who has taken flubromazepam is a medical emergency — do not wait to see if they improve.
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position (on their side with the top knee drawn forward) to prevent choking.
- 3. Monitor breathing continuously. If breathing stops, begin rescue breathing if trained.
- 4. Do not induce vomiting.
- 5. Do not leave the person alone.
What to tell the dispatcher: Name the substance (flubromazepam, a designer benzodiazepine), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Reversal agent: Flumazenil reverses benzodiazepine sedation but wears off in approximately 60 minutes — far shorter than flubromazepam's effects. Re-sedation is likely, and medical monitoring after administration is essential. Flumazenil can trigger seizures in benzodiazepine-dependent individuals.
Legal Status[edit]
Flubromazepam occupies an intermediate regulatory position: controlled in several major jurisdictions but not subject to international scheduling. The WHO Expert Committee on Drug Dependence reviewed flubromazepam at its 46th meeting in 2023 and concluded it did not meet the threshold for international control.[17] Scheduling varies by national legislation, and the compound remains legally accessible in jurisdictions without specific or blanket NPS controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (temporary) | DEA temporary emergency placement effective July 26, 2023; permanent status requires verification[8]safety citation needed |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Specifically scheduled May 2017; also covered by Psychoactive Substances Act 2016[7][18] |
| Canada | Schedule IV (CDSA) | Controlled Drugs and Substances Act[17] |
| Germany | Controlled (NpSG) | Neue-psychoaktive-Stoffe-Gesetz[17] |
| United Arab Emirates | Controlled | National psychoactive substance regulations[17] |
| International | Not under international control | WHO ECDD 46th review (2023) did not recommend scheduling[17] |
Analog act considerations
In jurisdictions without specific scheduling, flubromazepam may fall under structural analog legislation. The US Federal Analogue Act treats substances "substantially similar" to Schedule I/II controlled substances as controlled when intended for human consumption. Flubromazepam's structural similarity to scheduled benzodiazepines and its clear psychoactive intent in retail contexts make analog prosecution plausible. The synthesis and characterization of 12 positional isomers for forensic differentiation[19][20] reflects regulatory anticipation that structurally similar but technically distinct compounds may be marketed to circumvent controls.
Frequently asked questions
What is Flubromazepam?
Flubromazepam is a synthetic 1,4-benzodiazepine and GABA-A positive allosteric modulator with an elimination half-life exceeding 100 hours. First synthesized circa 1960 and never clinically developed, it emerged on research-chemical markets in late 2012.
How long does Flubromazepam last?
Total duration by route of administration — Oral: 6 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Flubromazepam?
Psychedex publishes a dosage table for Flubromazepam on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Flubromazepam?
The highest-severity documented interactions for Flubromazepam: Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Antipsychotics (Dangerous), Atypical antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Flubromazepam addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Flubromazepam: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with benzodiazepines, alcohol, barbiturates, other GABAergic CNS depressants. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3] ^abcdeLaing MK, Ti L, Marmel A, Tobias S, Shapiro AM, Laing R, Lysyshyn M, Socias ME (2021) An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program — International Journal on Drug Policy doi:10.1016/j.drugpo.2021.103169
- [4]
- [5]
- [6]
references
- [1]
- [2] ^abcJiang H, Hu Z, Yang L, Chen S, Tang D, Shi W, Qian H (2026) The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations — Medicinal Research Reviews doi:10.1002/med.70026
- [3]
- [4]
- [5]
- [6]